AIM To investigate the perioperative effect and clinical significance of recombinant human brain natriuretic peptide in valve replacement surgery for patients with low left ventricular ejection fraction (LVEF) valve.
METHODS Seventy patients with LVEF≤50% who underwent valve replacement surgery in our hospital from June 2020 to October 2021 were randomly divided into control group and observation group, with 35 cases in each group. The control group was treated with standard anti-heart failure drugs and the observation group was treated with recombinant human brain natriuretic peptide on the basis of standard anti-heart failure drugs. The perioperative cardiac function recovery related indicators (NT-proBNP, urine volume, LVEF value, FS value and changes of left ventricular end-diastolic diameter) in the two groups were compared and statistical analysis was conducted.
RESULTS There was no statistical difference in preoperative clinical indicators between the two groups. The level of NT-proBNP in observation group decreased 24 h and 72 h after medication, and urine volume increased 24 h and 72 h after medication. The duration of ventilator use and ICU were shortened and there were significant differences compared with those in control group (P<0.01). However, there was no significant difference in serum creatinine level between the two groups and the clinical outcomes (complication, cure and mortality) were not statistically significant.
CONCLUSION Perioperative use of recombinant human brain natriuretic peptide in valve replacement surgery for patients with low LVEF value is beneficial to postoperative cardiac function recovery, shortens the duration of ventilator use and ICU, but has no effect on serum creatinine level.
DownLoad: